ERYTECH Pharma S.A.
ISIN: FR0011471135 | Ticker: ERYP | LEI: 969500U8ZZCODU8A9374
Country: France
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer.
2004
Served areaWorldwide
Headquarters60 Avenue Rockefeller, 69008 Lyon – France
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 118,545,000.00 | 80,402,000.00 | 66,768,000.00 | 45,811,000.00 |
| Noncurrent Assets | N/A | 36,962,000.00 | 30,770,000.00 | 26,720,000.00 | 3,177,000.00 |
| Property Plant And Equipment | N/A | 25,632,000.00 | 20,862,000.00 | 18,960,000.00 | 393,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 603,000.00 | 589,000.00 | 15,000.00 | 5,000.00 |
| Other Noncurrent Assets | N/A | 718,000.00 | 1,091,000.00 | 876,000.00 | 195,000.00 |
| Current Assets | N/A | 81,583,000.00 | 49,632,000.00 | 40,048,000.00 | 42,634,000.00 |
| Inventories | N/A | 358,000.00 | 0.00 | 0.00 | 0.00 |
| Current Trade Receivables | N/A | 36,000.00 | 4,000.00 | 12,000.00 | 76,000.00 |
| Cash and cash equivalents | N/A | 73,173,000.00 | 44,446,000.00 | 33,699,000.00 | 38,789,000.00 |
| Other Current Assets | N/A | 8,016,000.00 | 5,182,000.00 | 6,337,000.00 | 3,769,000.00 |
| Equity And Liabilities | N/A | 118,545,000.00 | 80,402,000.00 | 66,768,000.00 | 45,811,000.00 |
| Equity | 145,602,000.00 | 85,560,000.00 | 26,539,000.00 | 22,845,000.00 | N/A |
| Issued Capital | N/A | 1,794,000.00 | 2,006,000.00 | 3,102,000.00 | 3,102,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | -73,300,000.00 | -53,797,000.00 | -228,000.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | -24,616,000.00 | -25,293,000.00 | -29,765,000.00 |
| Share Premium | N/A | 281,688,000.00 | 120,705,000.00 | 97,618,000.00 | 48,975,000.00 |
| Other Reserves | N/A | -136,607,000.00 | -24,616,000.00 | -25,293,000.00 | N/A |
| Equity Attributable To Owners Of Parent | N/A | 85,560,000.00 | 26,539,000.00 | 22,845,000.00 | 23,487,000.00 |
| Noncurrent Liabilities | N/A | 13,105,000.00 | 24,516,000.00 | 23,918,000.00 | 10,646,000.00 |
| Noncurrent Provisions | N/A | 506,000.00 | 652,000.00 | 524,000.00 | 419,000.00 |
| Deferred Tax Liabilities | N/A | 0.00 | 0.00 | 0.00 | 0.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 0.00 | 288,000.00 | 0.00 | 0.00 |
| Longterm Borrowings | N/A | 1,321,000.00 | 14,379,000.00 | 15,232,000.00 | 7,547,000.00 |
| Current Liabilities | N/A | 19,880,000.00 | 29,347,000.00 | 20,005,000.00 | 11,678,000.00 |
| Current Provisions | N/A | 71,000.00 | 0.00 | 0.00 | 314,000.00 |
| Trade And Other Current Payables | N/A | 13,775,000.00 | 20,910,000.00 | 14,154,000.00 | 5,115,000.00 |
| Current Derivative Financial Liabilities | N/A | 0.00 | 129,000.00 | 0.00 | 0.00 |
| Other Current Liabilities | N/A | 4,510,000.00 | 4,436,000.00 | 3,870,000.00 | 2,909,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 99,000.00 | 2,265,000.00 | 164,000.00 | 2,565,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | N/A |
| Revenue From Contracts With Customers | N/A | 0.00 | 0.00 | 0.00 |
| Other Income | 5,283,000.00 | 3,718,000.00 | 4,180,000.00 | 30,998,000.00 |
| Profit Loss From Operating Activities | -64,074,000.00 | -68,832,000.00 | -56,515,000.00 | -2,796,000.00 |
| Finance Income | 2,947,000.00 | 889,000.00 | 5,422,000.00 | 4,453,000.00 |
| Finance Costs | 1,533,000.00 | 5,354,000.00 | 2,702,000.00 | 1,364,000.00 |
| Income Tax Expense Continuing Operations | -1,000.00 | 3,000.00 | 2,000.00 | 521,000.00 |
| Profit (loss) | -62,659,000.00 | -73,300,000.00 | -53,797,000.00 | -228,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | -62,659,000.00 | -73,300,000.00 | -53,797,000.00 | -228,000.00 |
| Adjustments For Income Tax Expense | -1,000.00 | 3,000.00 | 2,000.00 | 521,000.00 |
| Adjustments For Decrease Increase In Inventories | 1,038,000.00 | 358,000.00 | 0.00 | 0.00 |
| Adjustments For Depreciation And Amortisation Expense | 4,216,000.00 | 4,991,000.00 | 5,377,000.00 | 4,619,000.00 |
| Adjustments For Provisions | 192,000.00 | 57,000.00 | 135,000.00 | 445,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 3,028,000.00 | -3,570,000.00 | -510,000.00 |
| Adjustments For Sharebased Payments | 1,359,000.00 | 1,179,000.00 | 1,323,000.00 | 447,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | 42,000.00 | 22,000.00 | 17,000.00 | -23,893,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 0.00 | 0.00 | 2,000.00 | 3,000.00 |
| Cash Flows From Used In Operating Activities | -43,310,000.00 | -51,720,000.00 | -56,770,000.00 | -31,764,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 0.00 | 83,000.00 | 0.00 | 37,630,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 20,117,000.00 | 1,139,000.00 | 298,000.00 | 85,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 16,000.00 | 2,000.00 | 0.00 | 0.00 |
| Proceeds From Other Longterm Assets Classified As Investing Activities | 414,000.00 | 4,000.00 | 145,000.00 | N/A |
| Purchase Of Other Longterm Assets Classified As Investing Activities | 119,000.00 | 421,000.00 | 192,000.00 | N/A |
| Cash Flows From Used In Investing Activities | -19,838,000.00 | -1,475,000.00 | -345,000.00 | 38,127,000.00 |
| Proceeds From Issuing Shares | 0.00 | 118,000.00 | 34,631,000.00 | 0.00 |
| Proceeds From Issuing Other Equity Instruments | 47,000.00 | 12,000.00 | 0.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | 0.00 | 27,134,000.00 | 12,157,000.00 | 3,081,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | 738,000.00 | 62,000.00 | 0.00 | 3,081,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 978,000.00 | 1,615,000.00 | 1,702,000.00 | 1,545,000.00 |
| Interest Paid Classified As Financing Activities | 195,000.00 | 326,000.00 | 374,000.00 | 223,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | 38,000.00 | 0.00 | 0.00 | N/A |
| Cash Flows From Used In Financing Activities | 40,000.00 | 25,449,000.00 | 44,712,000.00 | -1,768,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 1,910,000.00 | -981,000.00 | 1,656,000.00 | 495,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | -61,198,000.00 | -28,727,000.00 | -10,747,000.00 | 5,090,000.00 |
| Cash and cash equivalents | 73,173,000.00 | 44,446,000.00 | 33,699,000.00 | 38,789,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 23.06.23 | None | Other | Other | EUR 2,255,495.13 |
| 23.06.23 | None | Other | Other | EUR 43,821.79 |
| 23.06.23 | None | Other | Other | EUR 33,465.82 |
FR0011471135
LEI969500U8ZZCODU8A9374
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.